Top of page

NICE recommends Loncastuximab tesirine for DLBCL

Published on: 31 January 2024

New third line treatment available for relapsed or refractory diffuse large B-cell lymphoma.

Logo for the National Institute for Health and Care Excellence (NICE)

The National Institute for Health and Care Excellence (NICE) has recommended loncastuximab tesirine as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma in adults after 2 or more systemic therapies. The treatment option is only available if they have previously been treated with polatuzumab vedotin, or if polatuzumab vedotin is not suitable.

Loncastuximab tesirine is a type of targeted treatment, known as an antibody-drug conjugate. Antibody–drug conjugates are monoclonal antibodies joined to a chemotherapy drug. The antibody is designed to stick to a protein on lymphoma cells and carry the chemotherapy drug directly to them

Loncastuximab tesirine is an additional treatment option when CAR-T cell therapy is not suitable.

Find out more about drug development, approval and funding, or visit Lymphoma TrialsLink for the latest on clinical trials for lymphoma.